CEACAM1 Is Associated With an Immune‐Activated Tumor Microenvironment and Therapeutic Stratification in Sarcoma
International Journal of Genomics · 2026-01 · 2026 (1)
DOI: 10.1155/ijog/3351890 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Genomics, online erschienen am 30.04.2026. Verfasst von Ziqi Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Heilongjiang University of Chinese Medicine Affiliated Second Hospital, Harbin, 150001, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Carcinoembryonic antigen–related cell adhesion molecule 1 (CEACAM1) is a multifunctional immunomodulatory protein involved in both immune activation and immune suppression across diverse cancer types. However, its biological significance and clinical relevance in sarcoma (SARC) remain poorly defined. A comprehensive multiomics analysis of CEACAM1 was performed by integrating transcriptomic, genomic, epigenetic, immunological, and pharmacogenomic data from TCGA, GTEx, CPTAC, and large‐scale drug sensitivity datasets. CEACAM1 expression patterns, prognostic value, immune infiltration characteristics, pathway associations, genomic alterations, DNA methylation, transcriptional regulation, and therapeutic response were systematically evaluated. In SARC, elevated CEACAM1 expression was significantly associated with favorable clinical outcomes and characterized by an immune‐enriched tumor microenvironment. High CEACAM1 expression correlated with increased CD8 + T‐cell infiltration, enhanced interferon‐γ signaling, enrichment of tertiary lymphoid structure signatures, and upregulation of immune effector genes. Functional enrichment analyses further linked CEACAM1 to immune‐related pathways, including inflammatory response, interferon signaling, and apoptosis. At the therapeutic level, CEACAM1 expression was associated with reduced sensitivity to multiple chemotherapeutic agents, while concurrently correlating with enrichment of immunotherapy‐responsive gene signatures, indicating a distinct immune‐active yet therapeutically heterogeneous subtype of SARC. Collectively, these findings suggest that CEACAM1 represents a potential biomarker of immune activation and therapeutic stratification in SARC, warranting further investigation as a predictive indicator and immunotherapy‐related target in mesenchymal malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Heilongjiang University of Chinese Medicine Affiliated Second Hospital, Harbin, 150001, China.
- School of Medicine, Tongji University, Shanghai, 200092, China, tongji.edu.cn.
- Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.
- Department of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China, tongji.edu.cn.
ORCID-Profile: Minjue Shan, Yadong Guo, Mengmei Zhang, Ziyou Lin
Zitieren
APA
Cao, Z., Shan, M., Guo, Y., Zhang, M., & Lin, Z. (2026). CEACAM1 Is Associated With an Immune‐Activated Tumor Microenvironment and Therapeutic Stratification in Sarcoma. International Journal of Genomics, 2026(1). https://doi.org/10.1155/ijog/3351890
Vancouver
Cao Z, Shan M, Guo Y, Zhang M, Lin Z. CEACAM1 Is Associated With an Immune‐Activated Tumor Microenvironment and Therapeutic Stratification in Sarcoma. International Journal of Genomics. 2026;2026(1). doi:10.1155/ijog/3351890
BibTeX
@article{Cao2026,
author = {Cao, Ziqi and Shan, Minjue and Guo, Yadong and Zhang, Mengmei and Lin, Ziyou},
title = {CEACAM1 Is Associated With an Immune‐Activated Tumor Microenvironment and Therapeutic Stratification in Sarcoma},
journal = {International Journal of Genomics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijog/3351890}
}
EUVIMED